FGF21 and metabolic dysfunction-associated steatohepatitis: In light of these findings, FGF21, a hepatokine with both lipid-lowering and anti-inflammatory properties (Meng et al., 2021; Guo et al., 2016), has been brought to the foreground as a promising potential therapeutic to treat NASH.